Compare FHN & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHN | BIO |
|---|---|---|
| Founded | 1864 | 1952 |
| Country | United States | United States |
| Employees | 7400 | 7450 |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 7.1B |
| IPO Year | N/A | N/A |
| Metric | FHN | BIO |
|---|---|---|
| Price | $22.10 | $264.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 4 |
| Target Price | $25.76 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 5.1M | 254.4K |
| Earning Date | 04-15-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.57 | $2.74 |
| Revenue Next Year | $4.19 | $3.05 |
| P/E Ratio | $13.42 | ★ $9.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.23 | $211.43 |
| 52 Week High | $26.56 | $343.12 |
| Indicator | FHN | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 41.88 |
| Support Level | $22.02 | $254.98 |
| Resistance Level | $23.08 | $264.68 |
| Average True Range (ATR) | 0.50 | 7.85 |
| MACD | 0.09 | 1.34 |
| Stochastic Oscillator | 46.51 | 28.93 |
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets. The Wholesale segment delivers industry-specific products and services, while the Corporate segment provides internal support functions like finance, risk, and audit.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.